… S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function …
Dose-escalating and pharmacological study of Oxaliplatin in adult cancer patients with impaired …

… dose of oxaliplatin due to a poor ECOG performance … study, the rate conversion surgery to
patients with oxaliplatin-based chemotherapy was about 40%. Even in patients with impaired …

… P National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and
pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National …

… oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients
with moderate renal impairment, … higher than in patients with no or mild renal impairment. The …

… Aging is associated with changes in the clinical pharmacology … examined in phase I
dose-escalating studies ranged from 20 to … , BSA, and renal function on the PK of oxaliplatin. PK of …

… The primary goal of phase I PK studies in patients with impaired renal function is to … PK
studies performed in cancer patients [26–32]. For example, oxaliplatin and imatinib PK studies …

… , patients with impaired kidney function have been excluded from phase 1 studies of … in
a population of 2,471 Caucasian adult cancer patients receiving carboplatin chemotherapy [32]. …

… patients enrolled in single-agent, adult phase 1 studies … from 0 of 340 patients to 2 of 340
patients for oxaliplatin, and by … kidney impairment in the general population of individuals with …

… poor outcomes and does not have an established treatment. … Early studies in the adult
population suggest a 19% decrease in … tubulointerstitial nephritis related to oxaliplatin, as well as …

… The mild hepatic impairment cohort was included in our study to confirm these prior results
… Hopkins University for pharmacologic analysis.) during the conduct of the study. MA Rudek …